Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-07-18 00:00:00 ET · period of report 2023-07-17 · accession 0001209191-23-042557 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-18 | 2023-07-17 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $355.00 | -7,828 | 118.9K | -6% | -$2.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-17 | S | D | 7,828 | $355.00 | 118,906 | D | — | — |